Calcitonin salmon regulatory update

FDA's Advisory Committee for Reproductive Health Drugs and the Drug Safety and Risk Management Advisory Committee will meet on March 5 to discuss whether the benefit of calcitonin salmon for postmenopausal osteoporosis outweighs a potential risk of cancer. Last year, EMA's CHMP recommended that calcitonin-containing medicines be used only for short-term treatment because of an increased risk of cancer associated with long-term use. The committee also said calcitonin has limited efficacy for treating postmenopausal osteoporosis and said the benefits of calcitonin-containing medicines for the indication do not outweigh the risks (see BioCentury, Aug. 13, 2012). ...